Impact of Antiplatelet Therapy in Heart DiseaseRenda G. · de Caterina R.
Institute of Cardiology and Center of Excellence on Aging, ‘G. d’Annunzio’ University, Chieti, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Because platelet activation plays an important pathophysiological role in acute coronary syndromes, antiplatelet agents are a mainstay of cardiovascular therapy, both in high-risk primary prevention and in secondary prevention. This is usually done with aspirin in all such cases, and adding a P2Y12 inhibitor in secondary prevention usually for 1 year after an acute coronary syndrome, especially after stent implantation. P2Y12 inhibitors include ticlopidine (now rarely used), clopidogrel, prasugrel, and ticagrelor. In the setting of high-risk acute coronary syndromes treated with percutaneous coronary interventions, the addition of a glycoprotein IIb/IIIa antagonist, especially abciximab, is contemplated. Conversely, the role of antiplatelet therapy in preventing stroke after atrial fibrillation has been recently downgraded in most risk classes, in favor of anticoagulants. This chapter provides a general overview of the use of antiplatelet agents in heart disease.
© 2012 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.